ELSEVIER

International Journal of Antimicrobial Agents 17 (2001) 533–537

INTERNATIONAL JOURNAL OF
Antimicrobial Agents

www.ischemo.org

Author index

Volume 17 (2001)

Ackermann, M.R., see Kalfa, V.C. **17**, 505
Akova, M., see Köseoğlu, Ö. **17**, 477
Alias, R., see Norazah, A. **17**, 411
Alonzo, V., see Nostro, A. **17**, 517
Alou, L., D. Sevillano, J.H. Bugella, F. Fuentes, M.L. Gómez-Lus and J. Prieto, Evaluation of two in vitro pharmacodynamic simulation models: microfiltration versus centrifugation–filtration **17**, 365
Al-Quorain, A.-A., see Al-Qurashi, A.R. **17**, 233
Al-Qurashi, A.R., F. El-Morsy and A.-A. Al-Quorain, Evolution of metronidazole and tetracycline susceptibility pattern in *Helicobacter pylori* at a hospital in Saudi Arabia **17**, 233
Amaral, L., see Viveiros, M. **17**, 225
Ambrose, P.G., see Owens, R.C., Jr. **17**, 483
Amicosante, G., see Luzzaro, F. **17**, 131
Amicosante, G., see Perilli, M. **17**, 45
Anderson, B.E., see Schaeffer, A.J. **17**, 245
Andriole, V., see Ronald, A.R. **17**, 343
Angela Cannatelli, M., see Nostro, A. **17**, 517
Araj, G.F., see Zouain, M.G. **17**, 209
Asherov, J., see Dan, M. **17**, 491

Baffa, S., see Simonetti, G. **17**, 389
Bajaksouzian, S., see Joloba, M.L. **17**, 395
Baquero, F., see Pérez-Vázquez, M. **17**, 371
Barbella, R., see Rodríguez, A.J. **17**, 531
Basso, M., see Costa, S.F. **17**, 147
Bastert, J., M. Schaller, H.C. Korting and E.G.V. Evans, Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts **17**, 81
Beheshti, M., see Reid, G. **17**, 317
Belloni, R., see Luzzaro, F. **17**, 131
Bellorin, E., see Rodríguez, A.J. **17**, 531
Beovič, B., see Čižman, M. **17**, 27
Bernard, L., see Matsiota-Bernard, P. **17**, 155
Bianchi, B., see Perilli, M. **17**, 45
Bianchi, C., see Luzzaro, F. **17**, 131
Bichler, K.-H., see Naber, K.G. **17**, 321
Biedenbach, D.J., see Rospide, M.F. **17**, 451
Bilikova, E., M. Gogova, I. Svetlansky, M. Lovaszova, E. Kadlubjakova, E. Pichnova and V. Krcmery, Clinical significance of high-level gentamicin resistance in enterococci causing bacteraemia **17**, 525
Bisignano, G., see Nostro, A. **17**, 517
Blandino, G., see Fera, M.T. **17**, 151
Blondeau, J.M., D. Vaughan, R. Laskowski and S. Borsos, Susceptibility of Canadian isolates of *Haemophilus influenzae*, *Moraxella catarrhalis* and *Streptococcus pneumoniae* to oral antimicrobial agents **17**, 457
Boccazzi, A., see Esposito, S. **17**, 189
Bolán-Mejía, C., see Roque, A. **17**, 383
Bonner, D.P., see Gradelski, E. **17**, 103
Borsos, S., see Blondeau, J.M. **17**, 457
Brade, V., see Hunfeld, K.-P. **17**, 203
Briggs, A., see Feldman, C. **17**, 177
Brogden, K.A., see Kalfa, V.C. **17**, 505
Brook, I., The role of β-lactamase producing bacteria and bacterial interference in streptococcal tonsillitis **17**, 439
Brühl, P., see Naber, K.G. **17**, 321
Bryskier, A., see Williams, J.D. **17**, 443
Bugella, J.H., see Alou, L. **17**, 365

Cantón, R., see Pérez-Vázquez, M. **17**, 371
Cao, Q., see Schaeffer, A.J. **17**, 245
Caravelli, B., see Perilli, M. **17**, 45
Carbone, M., see Fera, M.T. **17**, 151
Cerdeiras, M.P., M.J. Pianzzola and A. Vázquez, The antibacterial activity of *Commelina erecta* extracts **17**, 423
Chambers, S., see Ronald, A.R. **17**, 343
Chi, C.L., see Yeh, L.L.L. **17**, 521
Chiodo, F., see Manfredi, R. **17**, 511
Choong, S., S. Wood, C. Fry and H. Whitfield, Catheter associated urinary tract infection and encrustation **17**, 305
Chrisofos, M., see Giannopoulos, A. **17**, 221
Christensen, B., Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy? **17**, 283
Christidou, A., see Maraki, S. **17**, 465
Čižman, M., M. Gubina, M. Paragi, B. Beovič and G. Lešničar, Meningococcal disease in Slovenia (1993–1999): serogroups and susceptibility to antibiotics **17**, 27
Climent, A., see Rodríguez, J.C. **17**, 229
Costa, S.F., M. Newbaer, C.R. Santos, M. Basso, I. Soares and A.S.S. Levin, Nosocomial pneumonia: importance of recognition of aetiological agents to define an appropriate initial empirical therapy **17**, 147
Crisafi, G., see Nostro, A. **17**, 517
Currie, B.J., see Jenney, A.W.J. **17**, 109

Dan, M., F. Poch and J. Asherov, Crossover assessment of serum bactericidal activity of grepafloxacin, ofloxacin and clarithromycin against respiratory pathogens after oral administration to healthy volunteers **17**, 491
Demesova, D., see Krcmery, S. **17**, 279
Denstedt, J., see Reid, G. **17**, 317
Denton, M., see Mooney, L. **17**, 63
Deriu, A., see Zanetti, S. **17**, 407
Desai, N., see Verma, A. **17**, 123

PII: S0924-8579(01)00347-8

de Truchis, P., see Matsiota-Bernard, P. **17**, 155
Dhople, A.M., In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against *Mycobacterium ulcerans* **17**, 57
Domínguez, L., see Vela, A.I. **17**, 215
Dos Santos, C., see Ferrara, A. **17**, 401
Dubin, A., see Mak, P. **17**, 137
Duffy, C.F. and R.F. Power, Antioxidant and antimicrobial properties of some Chinese plant extracts **17**, 527
Duncan, J.L., see Schaeffer, A.J. **17**, 245
Duque, C., see Rodríguez, A.J. **17**, 531
Dutt, M. and G.K. Khuller, Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis **17**, 115

El-Morsy, F., see Al-Qurashi, A.R. **17**, 233
Esposito, S., S. Noviello, A. Boccazzi and P. Tonelli, Management of upper respiratory tract infections in primary care in Italy: a national survey **17**, 189
Evans, E.G.V., see Bastert, J. **17**, 81

Fadda, G., see Zanetti, S. **17**, 407
Feldman, C., H. White, J. O'Grady, A. Flitcroft, A. Briggs and G. Richards, An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia **17**, 177
Fera, M.T., M. Giannone, S. Pallio, A. Tortora, G. Blandino and M. Carbone, Antimicrobial activity and postantibiotic effect of flurithromycin against *Helicobacter pylori* strains **17**, 151
Fernández-Garayzábal, J.F., see Vela, A.I. **17**, 215
Ferrara, A., C. Dos Santos and A. Lupi, Effect of different antibacterial agents and surfactant protein-A (SP-A) on adherence of some respiratory pathogens to bronchial epithelial cells **17**, 401
Fisher, D.A., see Jenney, A.W.J. **17**, 109
Flitcroft, A., see Feldman, C. **17**, 177
Foustoukou, M., see Ioannidou, S. **17**, 195
Franceschini, N., see Perilli, M. **17**, 45
Franke, S., see Fünfstück, R. **17**, 253
Fry, C., see Choong, S. **17**, 305
Fuentes, F., see Alou, L. **17**, 365
Fukushima, K., see Hashimoto, K. **17**, 97
Fünfstück, R., S. Franke, M. Hellberg, U. Ott, B. Knöfel, E. Straube, M. Sommer and J. Hacker, Secretion of cytokines by uroepithelial cells stimulated by *Escherichia coli* and *Citrobacter* spp. **17**, 253
Fung-Tomc, J., see Gradelski, E. **17**, 103

García, A., see Rodríguez, A.J. **17**, 531
George, J.T., see Morrissey, I. **17**, 33
Ghani Kamel, A., see Norazah, A. **17**, 411
Giamarellos-Bourboulis, E.J., see Giannopoulos, A. **17**, 221
Giamarellou, H., see Giannopoulos, A. **17**, 221
Giamarellou, H., see Williams, J.D. **17**, 443
Giannone, M., see Fera, M.T. **17**, 151
Giannopoulos, A., G. Koratzanis, E.J. Giamarellos-Bourboulis, I. Stinios, M. Chrisofos, M. Giannopoulou and H. Giamarellou, Pharmacokinetics of intravenously administered pefloxacin in the prostate; perspectives for its application in surgical prophylaxis **17**, 221
Giannopoulou, M., see Giannopoulos, A. **17**, 221
Gillespie, S.H., Antibiotic resistance in the absence of selective pressure **17**, 171
Gizzi, G., see Perilli, M. **17**, 45
Gogova, M., see Bilikova, E. **17**, 525
Gomez-Gil, B., see Roque, A. **17**, 383
Gómez-Lus, M.L., see Alou, L. **17**, 365
Gould, G.M., see Williams, J.D. **17**, 443
Gradelski, E., B. Kolek, D.P. Bonner, L. Valera, B. Minassian and J. Fung-Tomc, Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents **17**, 103
Graham, D.Y., see Osato, M.S. **17**, 39
Gubina, M., see Čižman, M. **17**, 27
Gür, D. and S. Ünal, Resistance to antimicrobial agents in Mediterranean countries **17**, 21
Gür, D., see Köseoğlu, Ö. **17**, 477
Gyssens, I.C., Quality measures of antimicrobial drug use **17**, 9

Habash, M., see Reid, G. **17**, 317
Hacker, J., see Fünfstück, R. **17**, 253
Hann, I.M. and H.G. Prentice, Lipid-based amphotericin B: a review of the last 10 years of use **17**, 161
Hashimoto, H., see Kumon, H. **17**, 311
Hashimoto, K., K. Yanagi, K. Fukushima and Y. Uda, Effect of 3-hydroxymethylene-2-thioxopyrrolidine on growth of two species of mutans streptococci and their in vitro plaque formation **17**, 97
Hatvani, N., Antibacterial effect of the culture fluid of *Lentinus edodes* mycelium grown in submerged liquid culture **17**, 71
Hellberg, M., see Fünfstück, R. **17**, 253
Hill, R.L.R., see Verma, A. **17**, 123
Høiby, N., see Williams, J.D. **17**, 443
Hofstetter, A.G., see Naber, K.G. **17**, 321
Hooton, T.M., Recurrent urinary tract infection in women **17**, 259
Hooton, T.M., see Ronald, A.R. **17**, 343
Hromec, J., see Krcmery, S. **17**, 279
Hunfeld, K.-P., J. Weigand, T.A. Wichelhaus, E. Kekoukh, P. Kraiczy and V. Brade, In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against *Borrelia burgdorferi* **17**, 203

Ioannidou, S., P.T. Tassios, A. Kotsovili-Tseleni, M. Foustoukou, N.J. Legakis and A. Vatopoulos, Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children **17**, 195
Iwatsubo, E., see Matsumoto, T. **17**, 293

Jacobs, M.R., see Joloba, M.L. **17**, 395
Jenney, A.W.J., G. Lum, D.A. Fisher and B.J. Currie, Antibiotic susceptibility of *Burkholderia pseudomallei* from tropical northern Australia and implications for therapy of melioidosis **17**, 109
Johnson, A.P., M. Warner and D.M. Livermore, Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance **17**, 377
Johnson, J., see Ronald, A.R. **17**, 343
Joloba, M.L., S. Bajaksouzian, E. Palavecino, C. Whalen and M.R. Jacobs, High prevalence of carriage of antibiotic-resistant *Streptococcus pneumoniae* in children in Kampala Uganda **17**, 395
Jones, R.N., see Rospide, M.F. **17**, 451
Jurga, L., see Krcmery, V. **17**, 419

Kadlubjakova, E., see Bilikova, E. **17**, 525
Kalfa, V.C., D. Palmquist, M.R. Ackermann and K.A. Brogden, Suppression of *Mannheimia* (*Pasteurella*) *haemolytica* serovar 1 infection in lambs by intrapulmonary administration of ovine antimicrobial anionic peptide **17**, 505
Kaur, D. and G.K. Khuller, In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria **17**, 51
Kawakami, Y., see Matsumoto, T. **17**, 293
Kehrenberg, C., see Schwarz, S. **17**, 431
Kekoukh, E., see Hunfeld, K.-P. **17**, 203
Kerr, K.G., see Mooney, L. **17**, 63
Khan, M.Y., A.J. Kinsara, A.O. Osoba, S. Wali, Y. Samman and Z. Memish, Increasing resistance of *M. tuberculosis* to anti-TB drugs in Saudi Arabia **17**, 415
Khuller, G.K., see Dutt, M. **17**, 115

Khuller, G.K., see Kaur, D. **17**, 51
Kicinska, A., see Mak, P. **17**, 137
Kinsara, A.J., see Khan, M.Y. **17**, 415
Knöfel, B., see Fünfstück, R. **17**, 253
Kobayashi, H., Airway biofilm disease **17**, 351
Kocagöz, S., see Köseoğlu, Ö. **17**, 477
Koh, Y.T., see Norazah, A. **17**, 411
Kolář, M., K. Urbánek and T. Látal, Antibiotic selective pressure and development of bacterial resistance **17**, 357
Kolek, B., see Gradelski, E. **17**, 103
Konorev, M.R., Eradication of *Helicobacter pylori* from the stomach and duodenum of patients with duodenal ulcers **17**, 425
Koratzanis, G., see Giannopoulos, A. **17**, 221
Korting, H.C., see Bastert, J. **17**, 81
Köseoğlu, Ö., S. Kocagöz, D. Gür and M. Akova, Nosocomial bloodstream infections in a Turkish university hospital: study of Gram-negative bacilli and their sensitivity patterns **17**, 477
Kotsovili-Tseleni, A., see Ioannidou, S. **17**, 195
Kraiczy, P., see Hunfeld, K.-P. **17**, 203
Krcmery, S., J. Hromec and D. Demesova, Treatment of lower urinary tract infection in pregnancy **17**, 279
Krcmery, V., L. Jurga, F. Mateicka and M. Šulcová, Fungaemia in elderly patients **17**, 419
Krcmery, V., see Bilikova, E. **17**, 525
Krieger, J., see Ronald, A.R. **17**, 343
Kumon, H., H. Hashimoto, M. Nishimura, K. Monden and N. Ono, Catheter-associated urinary tract infections: impact of catheter materials on their management **17**, 311
Kunishima, Y., see Matsukawa, M. **17**, 327

Lacy, M.K., see Nicolau, D.P. **17**, 497
Lakatos, M., see Rodríguez, A.J. **17**, 531
Laskowski, R., see Blondeau, J.M. **17**, 457
Látal, T., see Kolář, M. **17**, 357
Latre, M.V., see Vela, A.I. **17**, 215
Lebert, C., see Naber, K.G. **17**, 321
Legakis, N.J., see Ioannidou, S. **17**, 195
Lešničar, G., see Čižman, M. **17**, 27
Levin, A.S.S., see Costa, S.F. **17**, 147
Li, J.-T., see Zhang, Y.-L. **17**, 143
Lim, J.-h. and H.-i. Yun, Postantibiotic effects and postantibiotic sub-MIC effects of erythromycin, roxithromycin, tilmicosin, and tylosin on *Pasteurella multocida* **17**, 471
Lim, V.K.E., see Norazah, A. **17**, 411
Livermore, D.M., see Johnson, A.P. **17**, 377
Lombardi, G., see Luzzaro, F. **17**, 131
Lovaszova, M., see Bilikova, E. **17**, 525
Loza, E., see Pérez-Vázquez, M. **17**, 371
Ludwig, E., see Ronald, A. **17**, 287
Lum, G., see Jenney, A.W.J. **17**, 109
Lupi, A., see Ferrara, A. **17**, 401
Luzzaro, F., M. Perilli, G. Amicosante, G. Lombardi, R. Belloni, A. Zollo, C. Bianchi and A. Toniolo, Properties of multidrug-resistant, ESBL-producing *Proteus mirabilis* isolates and possible role of β-lactam/β-lactamase inhibitor combinations **17**, 131

MacLean, A.B., Urinary tract infection in pregnancy **17**, 273
Mak, P., A. Szewczyk, B. Mickowska, A. Kicinska and A. Dubin, Effect of antimicrobial apomyoglobin 56–131 peptide on liposomes and planar lipid bilayer membrane **17**, 137
Manabe, N., see Matsumoto, T. **17**, 293
Mancinelli, A., see Perilli, M. **17**, 45
Manfredi, R. and F. Chiodo, Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease **17**, 511
Maraki, S., A. Christidou and Y. Tselentis, Antimicrobial resistance and serotype distribution of *Streptococcus pneumoniae* isolates from Crete, Greece **17**, 465
Mateicka, F., see Krcmery, V. **17**, 419
Matsiota-Bernard, P., G. Vrioni, C. Onody, L. Bernard, P. de Truchis and C. Peronne, Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV–HCV co-infected patients **17**, 155
Matsukawa, M., Y. Kunishima, S. Takahashi, K. Takeyama and T. Tsukamoto, *Staphylococcus aureus* bacteriuria and surgical site infections by methicillin-resistant *Staphylococcus aureus* **17**, 327
Matsumoto, T., K. Takahashi, N. Manabe, E. Iwatsubo and Y. Kawakami, Urinary tract infection in neurogenic bladder **17**, 293
McNabb, J.C., see Nicolau, D.P. **17**, 497
Meijomil, P., see Rodríguez, A.J. **17**, 531
Memish, Z., see Khan, M.Y. **17**, 415
Mendoza, M., see Rodríguez, A.J. **17**, 531
Mickowska, B., see Mak, P. **17**, 137
Minassian, B., see Gradelski, E. **17**, 103
Molina-Aja, A., see Roque, A. **17**, 383
Molina, N., see Rodríguez, A.J. **17**, 531
Monden, K., see Kumon, H. **17**, 311
Mooney, L., K.G. Kerr and M. Denton, Survival of *Stenotrophomonas maltophilia* following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients **17**, 63
Moreno, M.A., see Vela, A.I. **17**, 215
Morrissey, I. and J.T. George, Measurement of the bactericidal activity of fluoroquinolones against *Streptococcus pneumoniae* using the bactericidal index method **17**, 33

Naber, K.G., **17**, 243
Naber, K.G., A.G. Hofstetter, P. Brühl, K.-H. Bichler and C. Lebert, Guidelines for the perioperative prophylaxis in urological interventions of the urinary and male genital tract **17**, 321
Naber, K.G., see Ronald, A.R. **17**, 343
Naber, K.G., see Williams, J.D. **17**, 443
Naber, K.G., Which fluoroquinolones are suitable for the treatment of urinary tract infections? **17**, 331
Newbaer, M., see Costa, S.F. **17**, 147
Nicolau, D.P., J.C. McNabb, M.K. Lacy, R. Quintiliani and C.H. Nightingale, Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia **17**, 497
Nicolau, D.P., see Owens, R.C., Jr. **17**, 483
Nicolle, L.E., see Ronald, A.R. **17**, 343
Nightingale, C.H., see Nicolau, D.P. **17**, 497
Nightingale, C.H., see Owens, R.C., Jr. **17**, 483
Nishimura, M., see Kumon, H. **17**, 311
Norazah, A., Y.T. Koh, A. Ghani Kamel, R. Alias and V.K.E. Lim, Mupirocin resistance among Malaysian isolates of methicillin-resistant *Staphylococcus aureus* **17**, 411
Norton, R.E., S. Patole and J. Whitehall, An in vitro study of the efficacy of rifampicin and minocycline coated umbilical venous catheters **17**, 237
Nostro, A., G. Bisignano, M. Angela Cannatelli, G. Crisafi, M. Paola Germanò and V. Alonzo, Effects of *Helichrysum italicum* extract on growth and enzymatic activity of *Staphylococcus aureus* **17**, 517
Noviello, S., see Esposito, S. **17**, 189

Odenholt, I., Pharmacodynamic effects of subinhibitory antibiotic concentrations **17**, 1
O'Grady, J., see Feldman, C. **17**, 177
Oliver, A., see Pérez-Vázquez, M. **17**, 371
Onody, C., see Matsiota-Bernard, P. **17**, 155
Ono, N., see Kumon, H. **17**, 311
Orrett, F.A., Antimicrobial sensitivity pattern of aerobic bacteria blood isolates: experience at a university hospital in Trinidad **17**, 75

Osato, M.S., R. Reddy, S.G. Reddy, R.L. Penland and D.Y. Graham, Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant *Helicobacter pylori* **17**, 39
Osoba, A.O., see Khan, M.Y. **17**, 415
Ott, U., see Fünfstück, R. **17**, 253
Owens, R.C., Jr., P. Tessier, C.H. Nightingale, P.G. Ambrose, R. Quintiliani and D.P. Nicolau, Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens **17**, 483

Palavecino, E., see Joloba, M.L. **17**, 395
Pallio, S., see Fera, M.T. **17**, 151
Palmquist, D., see Kalfa, V.C. **17**, 505
Paola Germanò, M., see Nostro, A. **17**, 517
Paragi, M., see Čižman, M. **17**, 27
Patole, S., see Norton, R.E. **17**, 237
Penland, R.L., see Osato, M.S. **17**, 39
Pérez-Vázquez, M., A. Oliver, B. Sánchez del Saz, E. Loza, F. Baquero and R. Cantón, Performance of the VITEK2 system for identification and susceptibility testing of routine Enterobacteriaceae clinical isolates **17**, 371
Perilli, M., B. Segatore, N. Franceschini, G. Gizzi, A. Mancinelli, B. Caravelli, D. Setacci, M.M. Tavio-Perez, B. Bianchi and G. Amicosante, Ceftibuten stability to active-site serine and metallo-ß-lactamases **17**, 45
Perilli, M., see Luzzaro, F. **17**, 131
Periti, P., see Williams, J.D. **17**, 443
Peronne, C., see Matsiota-Bernard, P. **17**, 155
Philpott-Howard, J., *Antimicrobial Chemotherapy*, 4th edition, Edited by David Greenwood, Oxford University Press, 2000; 413 p. ISBN 0-19-263195-0; Price: £29.95 **17**, 427
Philpott-Howard, J., see Verma, A. **17**, 123
Pianzzola, M.J., see Cerdeiras, M.P. **17**, 423
Pichnova, E., see Bilikova, E. **17**, 525
Poch, F., see Dan, M. **17**, 491
Power, R.F., see Duffy, C.F. **17**, 527
Prentice, H.G., see Hann, I.M. **17**, 161
Prieto, J., see Alou, L. **17**, 365
Pruden, D.L., see Schaeffer, A.J. **17**, 245

Quintiliani, R., see Nicolau, D.P. **17**, 497
Quintiliani, R., see Owens, R.C., Jr. **17**, 483

Rajan, N., see Schaeffer, A.J. **17**, 245
Ratjen, F., Changes in strategies for optimal antibacterial therapy in cystic fibrosis **17**, 93
Raz, R., Postmenopausal women with recurrent UTI **17**, 269
Reddy, R., see Osato, M.S. **17**, 39
Reddy, S.G., see Osato, M.S. **17**, 39
Reid, G., M. Habash, D. Vachon, J. Denstedt, J. Riddell and M. Beheshti, Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation **17**, 317
Richards, G., see Feldman, C. **17**, 177
Riddell, J., see Reid, G. **17**, 317
Rodríguez, A.A., see Vela, A.I. **17**, 215
Rodríguez, A.J., C.N. Rodríguez, P. Meijomil, A. García, C. Duque, N. Molina, R. Barbella, M. Lakatos, E. Bellorin and M. Mendoza, In vitro activity of quinolones against isolates from paediatric urinary tract infections from three Venezuelan centres **17**, 531
Rodríguez, C.N., see Rodríguez, A.J. **17**, 531
Rodríguez, J.C., M. Ruiz, A. Climent and G. Royo, In vitro activity of four fluoroquinolones against *Mycobacterium tuberculosis* **17**, 229
Romano, L., see Zanetti, S. **17**, 407
Ronald, A. and E. Ludwig, Urinary tract infections in adults with diabetes **17**, 287
Ronald, A.R., L.E. Nicolle, E. Stamm, J. Krieger, J. Warren, A. Schaeffer, K.G. Naber, T.M. Hooton, J. Johnson, S. Chambers and V. Andriole, Urinary tract infection in adults: research priorities and strategies **17**, 343
Roque, A., A. Molina-Aja, C. Bolán-Mejía and B. Gomez-Gil, In vitro susceptibility to 15 antibiotics of vibrios isolated from penaeid shrimps in Northwestern Mexico **17**, 383
Rospide, M.F., D.J. Biedenbach and R.N. Jones, Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and *Haemophilus influenzae* **17**, 451
Rouveix, B., see Williams, J.D. **17**, 443
Royo, G., see Rodríguez, J.C. **17**, 229
Ruiz, M., see Rodríguez, J.C. **17**, 229

Samman, Y., see Khan, M.Y. **17**, 415
Sánchez del Saz, B., see Pérez-Vázquez, M. **17**, 371
Santos, C.R., see Costa, S.F. **17**, 147
Schaeffer, A.J., N. Rajan, Q. Cao, B.E. Anderson, D.L. Pruden, J. Sensibar and J.L. Duncan, Host pathogenesis in urinary tract infections **17**, 245
Schaeffer, A., see Ronald, A.R. **17**, 343
Schaller, M., see Bastert, J. **17**, 81
Schwarz, S., C. Kehrenberg and T.R. Walsh, Use of antimicrobial agents in veterinary medicine and food animal production **17**, 431
Sechi, L.A., see Zanetti, S. **17**, 407
Segatore, B., see Perilli, M. **17**, 45
Sensibar, J., see Schaeffer, A.J. **17**, 245
Setacci, D., see Perilli, M. **17**, 45
Sevillano, D., see Alou, L. **17**, 365
Shannon, K., see Verma, A. **17**, 123
Simonetti, G., S. Baffa and N. Simonetti, Contact imidazole activity against resistant bacteria and fungi **17**, 389
Simonetti, N., see Simonetti, G. **17**, 389
Soares, I., see Costa, S.F. **17**, 147
Sommer, M., see Fünfstück, R. **17**, 253
Spanu, T., see Zanetti, S. **17**, 407
Stamm, E., see Ronald, A.R. **17**, 343
Stinios, I., see Giannopoulos, A. **17**, 221
Straube, E., see Fünfstück, R. **17**, 253
Šulcová, M., see Krcmery, V. **17**, 419
Svetlansky, I., see Bilikova, E. **17**, 525
Szewczyk, A., see Mak, P. **17**, 137

Takahashi, K., see Matsumoto, T. **17**, 293
Takahashi, S., see Matsukawa, M. **17**, 327
Takeyama, K., see Matsukawa, M. **17**, 327
Tassios, P.T., see Ioannidou, S. **17**, 195
Tavio-Perez, M.M., see Perilli, M. **17**, 45
Tessier, P., see Owens, R.C., Jr. **17**, 483
Thakur, C.P., A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study **17**, 67
Tonelli, P., see Esposito, S. **17**, 189
Toniolo, A., see Luzzaro, F. **17**, 131
Tortora, A., see Fera, M.T. **17**, 151
Tselentis, Y., see Maraki, S. **17**, 465
Tsukamoto, T., see Matsukawa, M. **17**, 327

Uda, Y., see Hashimoto, K. **17**, 97
Ünal, S., see Gür, D. **17**, 21
Urbánek, K., see Kolář, M. **17**, 357

Vachon, D., see Reid, G. **17**, 317
Valera, L., see Gradelski, E. **17**, 103
Vatopoulos, A., see Ioannidou, S. **17**, 195
Vaughan, D., see Blondeau, J.M. **17**, 457
Vázquez, A., see Cerdeiras, M.P. **17**, 423

Vela, A.I., J.F. Fernández-Garayzábal, M.V. Latre, A.A. Rodríguez, L. Domínguez and M.A. Moreno, Antimicrobial susceptibility of *Listeria monocytogenes* isolated from meningoencephalitis in sheep **17**, 215
Verma, A., N. Desai, K. Shannon, J. Philpott-Howard and R.L.R. Hill, Intra- and inter-generic plasmid-mediated spread of cephalosporin and aminoglycoside resistance amongst *Klebsiella aerogenes* K41 and other enterobacteria **17**, 123
Viveiros, M. and L. Amaral, Enhancement of antibiotic activity against poly-drug resistant *Mycobacterium tuberculosis* by phenothiazines **17**, 225
Vrioni, G., see Matsiota-Bernard, P. **17**, 155

Wali, S., see Khan, M.Y. **17**, 415
Walsh, T.R., see Schwarz, S. **17**, 431
Warner, M., see Johnson, A.P. **17**, 377
Warren, J., see Ronald, A.R. **17**, 343
Warren, J.W., Catheter-associated urinary tract infections **17**, 299
Weigand, J., see Hunfeld, K.-P. **17**, 203
Whalen, C., see Joloba, M.L. **17**, 395
Whitehall, J., see Norton, R.E. **17**, 237
White, H., see Feldman, C. **17**, 177
Whitfield, H., see Choong, S. **17**, 305
Wichelhaus, T.A., see Hunfeld, K.-P. **17**, 203
Williams, J.D., K.G. Naber, A. Bryskier, N. Høiby, I.M. Gould, P. Periti, H. Giamarellou and B. Rouveix, Classification of oral cephalosporins. A matter for debate **17**, 443
Wood, S., see Choong, S. **17**, 305

Yanagi, K., see Hashimoto, K. **17**, 97
Yeh, L.L.L. and C.L. Chi, Another look at differences in the susceptibility of *Escherichia coli* and *Klebsiella pneumoniae* to cephalothin and cefazolin **17**, 521
Yun, H.-i., see Lim, J.-h. **17**, 471

Zanetti, S., T. Spanu, A. Deriu, L. Romano, L.A. Sechi and G. Fadda, In vitro susceptibility of *Vibrio* spp. isolated from the environment **17**, 407
Zhang, Y.-L. and J.-T. Li, The in vitro activity of sulbactam combined with third generation cephalosporins against third generation cephalosporin-resistant bacteria **17**, 143
Zollo, A., see Luzzaro, F. **17**, 131
Zouain, M.G. and G.F. Araj, Antimicrobial resistance of Enterococci in Lebanon **17**, 209